A recent study provided evidence that Isavuconazole is useful for the prevention of Invasive fungal infections (IFIs) in the hematologic context. IFIs are most likely to develop in people suffering from haematologic malignancies. Azoles are suggested by current guidelines for IFI prophylaxis. Nonetheless, antifungal prophylaxis is frequently utilized off-label in clinical settings.

To offer best information to haematologists on the safety and efficiency of Isavuconazole in IFI prevention in real-world and interventional, observational trials, a systematic literature review was carried out. Studies addressing the benefits of Isavuconazole prophylaxis in people at high risk of IFI were searched using databases such as Embase, MEDLINE, and Cochrane Library, as well as pertinent conference proceedings and clinical trial registries. An evaluation of the studies' risk of bias and inclusion was done.

Nine research fulfilled the criteria for inclusion. Eight of these studies either involved haematologic populations (people undergoing haematopoietic stem cell transplantation, those with acute myeloid leukaemia or myelodysplastic syndromes; n = 5) or encompassed haematologic populations (n = 3).

These results favor Isavuconazole as a substitute azole for prophylaxis in at-risk individuals. Although more research is required, Isavuconazole might be a valuable azole for IFI prevention in high-risk haematologic groups.